Medical Guide · 18 min
The most complete guide on semaglutide. How it works, what to expect month by month, side effects, cost, and who qualifies. All backed by clinical evidence and reviewed by physicians.
Semaglutide is an injectable medication in the family of GLP-1 receptor agonists (glucagon-like peptide-1). It was originally developed to treat type 2 diabetes and FDA-approved in 2017 under the brand name Ozempic®. In 2021, the FDA approved the same molecule at a higher dose specifically for weight loss, under the brand name Wegovy®. Same active molecule — the difference is dose and product label.
Beyond diabetes, semaglutide has become one of the most-studied medications for obesity, with large clinical trials showing sustained weight loss, blood pressure improvement, reduced cardiovascular risk, and improvements in metabolic markers like hemoglobin A1c and lipids.
Semaglutide mimics a hormone called GLP-1 that your body produces naturally in the gut after eating. Natural GLP-1 only lasts a few minutes in the bloodstream; semaglutide has a half-life of about one week, enabling a once-weekly injection.
It acts on three main systems:
The most cited clinical trial is STEP 1, published in the New England Journal of Medicine in 2021. It included 1,961 adults without diabetes with BMI ≥30 (or class 1 obesity with a comorbidity). Participants on 2.4 mg semaglutide weekly lost an average of 14.9% of body weight over 68 weeks, compared to 2.4% in the placebo group.
For perspective: for a woman weighing 200 pounds (90 kg), that's an average loss of about 30 pounds (13.5 kg). A third of participants lost more than 20% of body weight.
Individual results vary by: maximum dose reached (many patients don't get to 2.4 mg), adherence to weekly injections, parallel diet and activity changes, and genetic factors. It's not a "magic drug" — it works best combined with lifestyle changes and ongoing medical follow-up.
Semaglutide for weight loss always starts with a low dose and increases gradually ("titration") every 4 weeks. The standard schedule is:
The slow titration exists to minimize gastrointestinal side effects. If side effects are intolerable at any dose, a physician can extend the time at that dose or keep you at a lower dose permanently if results are good there.
The most common side effects, reported in more than 10% of patients in STEP 1, are gastrointestinal:
Rare but serious side effects requiring immediate medical attention:
Absolute contraindication: personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2). Semaglutide carries an FDA "black box warning" for this reason — although the risk was observed in rats and not humans, the FDA maintains the warning out of caution.
The FDA approved semaglutide 2.4 mg (Wegovy®) for weight loss in:
Not a candidate for semaglutide:
A licensed physician must review your full medical history, current medications, allergies, and goals before prescribing. At REMEVi this review happens within 24 hours of the eligibility quiz.
Brand semaglutide (Ozempic® for diabetes, Wegovy® for weight loss) is manufactured by Novo Nordisk and went through the full FDA approval process. It's the gold standard — and the most expensive. Without insurance, list prices run $900–$1,400 per month.
Compounded semaglutide is prepared by FDA-authorized compounding pharmacies under an individual physician prescription. These pharmacies source the active ingredient (semaglutide sodium) from FDA-registered suppliers and prepare patient-specific doses. It's not a generic — generics only exist after a patent expires, and semaglutide's patent has not. Compounding is a parallel legal pathway.
Important considerations:
Actual cost depends on factors like manufacturer discounts, insurance coverage (many plans don't cover weight-loss medications), and geography. REMEVi's price is direct-pay — transparent, no insurance, no fine print.
Semaglutide is an injectable medication in the GLP-1 family (glucagon-like peptide-1 receptor agonists). It was originally FDA-approved in 2017 for type 2 diabetes under the brand name Ozempic®, and then in 2021 for weight loss under the brand name Wegovy®. Same molecule — different dose and label.
Semaglutide mimics a natural hormone called GLP-1 that your body produces in the gut. It works on three systems: it slows stomach emptying (you feel full longer), it acts on brain receptors that regulate appetite (reducing cravings and the mental "food chatter"), and it improves insulin sensitivity. The result: you eat less without feeling constantly hungry.
In the STEP 1 clinical trial (published in NEJM, 2021), patients taking 2.4 mg semaglutide weekly lost an average of 15% of body weight over 68 weeks, compared to 2.4% in the placebo group. Individual results vary — some patients lose 20%+, others less. Factors include achieved dose, adherence, diet, physical activity, and genetics.
The most reported side effects are: nausea (most common in the first 2–4 weeks), constipation, diarrhea, gas, fatigue, and reflux. Most are mild and improve with gradual dose titration. Rare but serious effects include pancreatitis, gallbladder issues, and increased risk of thyroid tumors in patients with a personal or family history of MTC or MEN2 (a contraindication).
Price varies dramatically: brand Wegovy® and Ozempic® run $900–$1,300/month without insurance. With insurance, coverage varies widely. Compounded semaglutide (prepared by FDA-registered pharmacies under a physician prescription) typically runs $200–$350/month without insurance. REMEVi offers compounded semaglutide from $249/month, medical review included.
Studies show most patients regain about two-thirds of the weight lost within a year of discontinuing. This is not a failure — it reflects that obesity is a chronic condition. Many patients taper down gradually rather than stopping abruptly, and pair the change with nutrition coaching and sustainable habits.
Semaglutide is FDA-approved for adults with a BMI ≥30, or BMI ≥27 with at least one related comorbidity (type 2 diabetes, hypertension, dyslipidemia, sleep apnea). Contraindications include: personal or family history of medullary thyroid carcinoma (MTC), MEN2 syndrome, pregnancy, breastfeeding, and severe pancreatitis. A physician must review your full history before prescribing.
Compounded semaglutide is prepared by FDA-authorized compounding pharmacies under an individual prescription. It contains the same active molecule (semaglutide) as Ozempic and Wegovy but does not go through the same final-product FDA approval process. It's a legal and legitimate option as long as the FDA keeps semaglutide on the shortage list or under a valid individual prescription.
A licensed bilingual physician reviews your medical history and decides if you qualify — within 24 hours of the quiz.
Start the quiz →Disclaimer: This guide is informational and not individual medical advice. The decision to use any medication should be made with a licensed physician who knows your full medical history.
No insurance required · Cancel anytime